Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · FibroBiologics, Inc. (FBLG)

FibroBiologics sells about $0.5 million of stock and warrants to its Chief Scientific Officer

Neutral Impact 2 of 5 financing Written later

FibroBiologics agreed on September 15, 2026 to sell 298,508 shares of common stock and accompanying warrants to Chief Scientific Officer Hamid Khoja, Ph.D., in a private placement. Gross proceeds are expected to be about $0.5 million, which the company plans to use for general corporate purposes and working capital, so the sale adds a small number of shares and potential future shares for existing holders.

Key points

  • Shares offered at $1.675 each, equal to the September 14, 2026 Nasdaq closing bid of $1.55 plus $0.125 per warrant
  • Warrants are exercisable at $1.55 per share, expire five years after issuance, and allow cashless exercise
  • Maximum of 298,508 shares could be issued on warrant exercise, subject to anti-dilution adjustments
  • The offering is expected to close on September 15, 2026, subject to customary closing conditions

The filing

CompanyFibroBiologics, Inc. (FBLG)
Form8-K, current report
Filed with the SECSep 15, 2026, 7:15 AM ET
Accession number0001193125-26-391310

Items reported: 1.01 Material Definitive Agreement3.02 Unregistered Equity Sale

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 15, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.